Actionnariat et activité des initiés pour Omeros Corporation (OMER): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $17.34 |
| Capitalisation | $1.3B |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $2.2M | $3.4M | $5.9M | $3.1M | $10.5M | $100.8M | $11.0M | $7.1M | $3.4M | $9.7M |
| Placements à Court Terme | $43.1M | $80.4M | $54.6M | $57.7M | $124.5M | $56.5M | $183.9M | $164.7M | $86.7M | $162.1M |
| Créances | $12.0M | $17.1M | $22.8M | $35.2M | $3.8M | $82.5M | $242.0M | $6.7M | $36.8M | $36.3M |
| Stocks | $1.1M | $443000 | $52.5M | $1.1M | $1.4M | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $60.3M | $108.4M | $89.9M | $103.7M | $151.3M | $248.0M | $443.2M | $217.9M | $134.1M | $215.7M |
| Immobilisations Corporelles | $1.2M | $2.1M | $3.8M | $30.9M | $28.1M | $30.0M | $23.3M | $20.6M | $17.6M | $12.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $67.3M | $116.3M | $95.9M | $137.0M | $181.0M | $419.3M | $591.0M | $378.3M | $277.1M | $325.6M |
| Dettes Fournisseurs | $2.5M | $6.7M | $6.3M | $5.3M | $4.2M | $13.4M | $6.0M | $7.7M | $5.9M | $4.8M |
| Dette à Court Terme | 0 | 0 | 0 | $3.5M | 0 | 0 | $94.4M | $8.6M | $21.0M | $17.1M |
| Passifs Courants | $16.1M | $26.3M | $37.4M | $55.5M | $36.7M | $51.8M | $136.4M | $53.3M | $79.5M | $78.1M |
| Dette à Long Terme | $79.5M | $83.3M | $149.0M | $158.2M | $236.3M | $313.5M | $220.9M | $329.7M | $166.6M | $208.5M |
| Passifs Totaux | $104.7M | $119.1M | -$4.2M | $246.0M | $301.8M | $395.5M | $505.3M | $403.3M | $459.7M | $446.9M |
| Réserves | -$469.9M | -$523.4M | $650.1M | -$734.6M | -$872.7M | -$683.1M | -$635.7M | -$753.5M | -$910.3M | -$913.7M |
| Capitaux Propres | -$37.4M | -$2.8M | $650.1M | -$109.0M | -$120.8M | $23.8M | $85.7M | -$25.0M | -$182.6M | -$121.2M |
| Dette Totale | $80.0M | $84.6M | $151.4M | $194.0M | $268.8M | $347.8M | $342.0M | $361.6M | $207.0M | $239.1M |
| Dette Nette | $34.7M | $858000 | $91.0M | $133.2M | $133.9M | $190.6M | $147.1M | $189.7M | $116.9M | $67.3M |
| Fonds de Roulement | $44.2M | $82.1M | $52.5M | $48.3M | $114.5M | $196.2M | $306.9M | $164.6M | $54.6M | $137.6M |
Santé financière
| Dette / Capitaux propres | -1.63 |
| Ratio de liquidité | 1.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.20 |
Rentabilité
| Rentabilité des capitaux propres | -109.40% |
| Rentabilité du capital investi | -31.14% |
| Rentabilité des actifs | 43.52% |
| Marge brute | 95.77% |
| Marge opérationnelle | -189.53% |
| Marge nette | 324.88% |
Entreprises liées: ADCT · BCYC · FDMT · FULC · GOSS · KALV · LXRX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de OMER: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions